The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: Siemens Medical Solutions
• Treatments: Regadenoson

Criteria

Inclusion Criteria:

• Referred for a clinically indicated PET-MPI

• Must provide written informed consent prior to any study-related procedures being performed

• Must be willing to comply with all clinical study procedures

Exclusion Criteria:

• Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post menopausal, with minimum one (1) year history without menses.

• Currently taking or has taken within 48 hours the following excluded medications:

• ActoPlus Met (Pioglitazone + metformin)

• Avandamet (Rosiglitazone + metformin)

• Fortamet (metformin)

• Glucovance (Glyburide +metformin)

• Glucophage (metformin)

• Glucophage extended-release (XR) (metformin)

• Glumetza (metformin

• Janumet (Sitagliptin + metformin)

• Metformin (metformin)

• Metaglip (Glipizide + metformin)

• Riomet (metformin)

• Active wheezing

• Asthma

• Implanted rhythm devices (pacemaker, defibrillator)

• Acute psychiatric disorder

• Unwilling to comply with the requirements of the protocol

• Previously entered this study

• Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study

• Suffers from claustrophobia

• Impaired renal function (GFR < 45 ml/min)

• Positive cardiac enzymes positive troponin, creatine kinase-MB (CK-MB), or myosin

• Acute hypotension (<100 mm Hg systolic)

• ST-elevations, new transient ST changes greater than 0.05mV or T- wave inversions with symptoms

• 2nd or 3rd degree atrioventricular (AV) block

• Previous Coronary Artery Bypass Graft (CABG) or stent placement